Rheumatoid Arthritis Clinical Trials in the UK (2026)
Rheumatoid arthritis affects approximately 450,000 adults in the UK and is one of the most active areas of rheumatology research. The treatment landscape includes conventional DMARDs, targeted synthetic DMARDs (JAK inhibitors), and a growing range of biologic therapies. Clinical trials continue to explore new mechanisms, biosimilars, and earlier intervention strategies.
Current RA Research Areas
Following tofacitinib, baricitinib, and upadacitinib, next-generation JAK inhibitors target more specific JAK family members (JAK1-selective, TYK2 inhibitors). Trials test safety profiles, long-term outcomes, and combinations with methotrexate in early disease.
Beyond TNF inhibitors and IL-6 receptor blockers, trials test antibodies targeting GM-CSF, CD40L, IL-1, and dual cytokine blockade. Some target tissue-resident cells rather than circulating immune cells.
As multiple biologics lose patent protection, large UK trials compare biosimilars to reference products for efficacy, immunogenicity, and safety. These trials provide access to state-of-the-art treatments at reduced drug development cost.
Trials for people at risk of developing RA (those with anti-CCP antibodies and joint pain but no clinical arthritis). The objective is to prevent or delay progression to full RA, using low-dose treatments before joint damage begins.
Treatment Lines and Trial Eligibility
- DMARD-naive — Trials testing early intensive therapy or treat-to-target with new combinations
- Inadequate response to MTX — The most common trial population. Tests adding a biologic or JAK inhibitor
- Inadequate response to TNF inhibitors — Trials of switching mechanisms (switching to IL-6, JAK, or CTLA4-Ig)
- Multiple prior biologic failures — Phase 2 and early access trials for novel mechanisms like GM-CSF or CD40 blockade
Key Eligibility Factors
- Moderate to severe active RA (DAS28 score ≥ 3.2, swollen and tender joint counts)
- Inflammatory markers — elevated CRP or ESR at screening
- Rheumatoid factor (RF) and/or anti-CCP antibody status — seropositive vs. seronegative
- Minimum number of prior DMARD or biologic treatments attempted
- TB and hepatitis screening — required before starting any biologic
- No recent infections requiring hospitalisation
Note: RA trials often include an active comparator arm, meaning you will receive an already-approved treatment even if you are not allocated to the experimental arm. Our Smart Matcher helps you find trials based on your prior treatments and serological status.
UK Trial Locations
- London — King's College Hospital, Guy's & St Thomas', UCLH
- Manchester — Salford Royal, Manchester Royal Infirmary
- Birmingham — Queen Elizabeth Hospital, Sandwell General
- Leeds — Chapel Allerton Hospital (NIHR Leeds BRC)
- Glasgow — Glasgow Royal Infirmary
- Edinburgh — Western General Hospital
- Nottingham — Nottingham University Hospitals
Find Your Matching Trials
Tell us about your RA, treatment history, and serology. We'll show you the most relevant recruiting trials.
Find My Matching Trials →Browse RA Trials Search All Trials